Patrick Burnett, MD, PhD: Results of CAMP 1 & 2 in Molluscum Contagiosum
Patrick Burnett reports impressive topline results from the CAMP 1 & 2 studies of investigational treatment VP-102.
The phase 3 studies, CAMP 1 and 2, investigated the safety and efficacy of the investigational treatment VP-102 in patients with molluscum contagiosum.
Patrick Burnett, MD, PhD, Chief Medical Officer of Verrica Pharmaceuticals and an investigator on the trials, spoke with MD Magazine® about the data at the 2019 Annual Meeting of the American Academy of Dermatology (AAD) in Washington, DC.
“The results showed that 54% and 46% of patients dosed with VP-102 did reach that complete clearance endpoint and that was compared to a placebo response rate of 13% and 18%,” said Burnett.
Burnett added that to meet the endpoint, patients had to have clearance of both lesions they started with as well as any new lesions that appeared during the trial.
The presentation, “CAMP-1 (Cantharidin Application in Molluscum Patients) and CAMP-2: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Studies Investigating VP-102,” was given at a late-breaking session at the AAD Annual Meeting on Saturday, March 2, 2019.
MD Mag: What did the CAMP 1 & 2 trials investigate?
Burnett: CAMP 1 and 2 are phase 3 pivotal trials that Verrica Pharmaceuticals conducted in patients who have molluscum contagiosum. These trials are randomized, double blind, placebo-controlled, and they looked at patients who had molluscum contagiosum with any number of lesions. So, we included a lot of children, we allowed children ages 2 and up, and the primary endpoint for those studies is complete clearance of all lesions. So, patients, in order to be considered clear, had to reach that by clearing not just the ones that they came into the study [with], but also any that they might have had over the course of the 12 weeks of treatment. The way we administered the treatment was every 3 weeks, so they were dosed at week 0, 3, 6, and 9—so up to 4 treatments if they were required—and then at week 12 patients came back and we looked at whether or not they had any lesions remaining at that time. That's how we read out the primary endpoint.
What results did you see in patients treated with VP-102?
The results showed that 54% and 46% of patients dosed with VP-102 did reach that complete clearance endpoint and that was compared to a placebo response rate of 13% and 18% in the 2 clinical studies.
